The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-08. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
A 2005 meta-analysis of drug company data found no evidence that SSRIs increased the risk of suicide; however, important protective or hazardous effects could not be excluded. A 2005 review observed that suicide attempts are increased in those who use SSRIs as compared to placebo and compared to therapeutic interventions other than tricyclic antidepressants. No difference risk of suicide attempts was detected between SSRIs versus tricyclic antidepressants. A 2006 review suggests that the widespread use of antidepressants in the new "SSRI-era" appears to have led to a highly significant decline in suicide rates in most countries with traditionally high baseline suicide rates. The decline is particularly striking for women who, compared with men, seek more help for depression. Recent clinical data on large samples in the US, too, have revealed a protective effect of antidepressants against suicide. A 2006 meta-analysis of randomized controlled trials suggests that SSRIs increase suicide ideation compared with placebo. However, the observational studies suggest that SSRIs did not increase suicide risk more than older antidepressants. The researchers stated that if SSRIs increase suicide risk in some patients, the number of additional deaths is small because ecological studies have generally found that suicide mortality has declined (or at least not increased) as SSRI use has increased. An additional meta-analysis by the FDA in 2006 found an age-related effect of SSRIs. Among adults younger than 25 years, results indicated that there was a higher risk for suicidal behavior.
Imetelstat, sold under the brand name Rytelo, is an anti-cancer medication used for the treatment of myelodysplastic syndromes with transfusion-dependent anemia. Imetelstat is an oligonucleotide telomerase inhibitor. By blocking telomerase activity, imetelstat causes telomere shortening, inhibits the proliferation of malignant stem and progenitor cells and induces cell death, ultimately leading to a reduction in malignant clones. The most common adverse reactions include decreased platelets, decreased white blood cells, decreased neutrophils, increased aspartate aminotransferase, increased alkaline phosphatase, increased alanine aminotransferase, fatigue, prolonged partial thromboplastin time, arthralgia/myalgia, COVID-19 infections, and headache. Imetelstat was approved for medical use in the United States in June 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Common descent is a concept in evolutionary biology applicable when one species is the ancestor of two or more species later in time. According to modern evolutionary biology, all living beings could be descendants of a unique ancestor commonly referred to as the last universal common ancestor (LUCA) of all life on Earth. Common descent is an effect of speciation, in which multiple species derive from a single ancestral population. The more recent the ancestral population two species have in common, the more closely they are related. The most recent common ancestor of all currently living organisms is the last universal ancestor, which lived about 3.9 billion years ago. The two earliest pieces of evidence for life on Earth are graphite found to be biogenic in 3.7 billion-year-old metasedimentary rocks discovered in western Greenland and microbial mat fossils found in 3.48 billion-year-old sandstone discovered in Western Australia. All currently living organisms on Earth share a common genetic heritage, though the suggestion of substantial horizontal gene transfer during early evolution has led to questions about the monophyly (single ancestry) of life. 6,331 groups of genes common to all living animals have been identified; these may have arisen from a single common ancestor that lived 650 million years ago in the Precambrian. Universal common descent through an evolutionary process was first proposed by the British naturalist Charles Darwin in the concluding sentence of his 1859 book On the Origin of Species:
Sources: en.wikipedia.org
== Effects on Animals == Calciseptine has been examined in vivo and in vitro in all kinds of animals, but mostly in rats. Calciseptine relaxes precontracted rat (thoracic) aorta and decreases blood pressure drastically. The decrease in blood pressure shows a combination of short- and long-lasting effects. The early, acute onset took five minutes, and the effect could last for 120 minutes or longer. In addition, calciseptine had only a small effect on the heart rhythm, changing it only slightly. Furthermore, it can also relax the trachea rings in the lungs. These effects can be explained by the relaxing activity of calciseptine on various smooth muscle cells. The inhibitory effect of calciseptine results in a decreased or total disappearance of electric activity in these cells. The total inhibitory effect depends on the tissue: the cardiovascular system is the most vulnerable, while neuronal cells are less vulnerable and skeletal muscle cells are completely resistant. This difference in tissue sensitivity is probably caused by slight differences in the L-type calcium channels in these tissues. These effects can occur at low subjected amounts of 0.1 till 1 μM calciseptine. In mouse myotube the Ca2+ currents show higher amplitude after incubation in calciseptine (1 μM). This effect of calciseptine on the Ca2+ current develops relatively fast. Calciseptine changes the reversal potential of the Ca2+ current in mouse myotubes. In adult frog skeletal muscle fibers calciseptine also causes an increased Ca2+ current.
Keuning S, Janssen DB, Witholt B (1985). "Purification and characterization of hydrolytic haloalkane dehalogenase from Xanthobacter autotrophicus GJ10". J. Bacteriol. 163 (2): 635–9. doi:10.1128/JB.163.2.635-639.1985. PMC 219169. PMID 4019411. Scholtz R, Leisinger T, Suter F, Cook AM (1987). "Characterization of 1-chlorohexane halidohydrolase, a dehalogenase of wide substrate range from an Arthrobacter sp". J. Bacteriol. 169 (11): 5016–21. doi:10.1128/jb.169.11.5016-5021.1987. PMC 213902. PMID 3667524. Yokota T, Omori T, Kodama T (1987). "Purification and properties of haloalkane dehalogenase from Corynebacterium sp. strain m15-3". J. Bacteriol. 169 (9): 4049–54. doi:10.1128/jb.169.9.4049-4054.1987. PMC 213707. PMID 3624201. Poelarends GJ, van Hylckama Vlieg JE, Marchesi JR, Freitas Dos Santos LM, Janssen DB (1999). "Degradation of 1,2-dibromoethane by Mycobacterium sp. strain GP1". J. Bacteriol. 181 (7): 2050–8. doi:10.1128/JB.181.7.2050-2058.1999. PMC 93616. PMID 10094681. Poelarends GJ, Wilkens M, Larkin MJ, van Elsas JD, Janssen DB (1999). "Degradation of 1,3-dichloropropene by pseudomonas cichorii 170". Appl. Environ. Microbiol. 64 (8): 2931–6. doi:10.1128/AEM.64.8.2931-2936.1998. PMC 106795. PMID 9687453. Nagata Y, Miyauchi K, Damborsky J, Manova K, Ansorgova A, Takagi M (1997). "Purification and characterization of a haloalkane dehalogenase of a new substrate class from a gamma-hexachlorocyclohexane-degrading bacterium, Sphingomonas paucimobilis UT26". Appl. Environ. Microbiol. 63 (9): 3707–10. Bibcode:1997ApEnM..63.3707N. doi:10.1128/AEM.63.9.3707-3710.1997.
The field of AI safety is deeply intertwined with philosophical considerations, particularly in the realm of ethics. Deontological ethics, which emphasizes adherence to moral rules, has been proposed as a framework for aligning AI systems with human values. Some have suggested that by embedding deontological principles, AI systems can be guided to avoid actions that cause harm, ensuring their operations remain within ethical boundaries, but those suggestions have been questioned, with other alternatives being suggested as more promising.
=== RNP immunoprecipitation (RIP and CLIP) === RIP and CLIP both purify a specific RNA-binding protein in order to identify bound RNAs, thereby studying ribonucleoproteins (RNPs). In RIP, the co-purified RNAs are extracted and their enrichment is compared to control, which was originally done by microarray or RT-PCR. In CLIP, cells are UV crosslinked prior to lysis, followed by additional purification steps beyond standard immunoprecipitation, including partial RNA fragmentation, high-salt washing, SDS-PAGE separation and membrane transfer, and identification of direct RNA binding sites by cDNA sequencing.
Sources: en.wikipedia.org
=== EC 1.5.8 With a flavin or flavoprotein as acceptor === EC 1.5.8.1: dimethylamine dehydrogenase EC 1.5.8.2: trimethylamine dehydrogenase EC 1.5.8.3: sarcosine dehydrogenase EC 1.5.8.4: dimethylglycine dehydrogenase
Brain Basal ganglia Brain stem Medulla Midbrain Pons Cerebellum Cerebrum Cerebral cortex Hypothalamus Limbic system Amygdala Eyes (2) Pineal gland Pituitary gland Thyroid gland Parathyroid glands (4) Thorax
==== Adsorption ==== Adsorption is a mass transfer process in which a substance is transported from the liquid phase to the surface of a solid/liquid (adsorbent) and becomes physically and chemically bonded (adsorbate). Adsorption can be classified into two forms based on the type of attraction between the adsorbate and the adsorbent: physical and chemical adsorption, commonly known as physisorption and chemisorptions.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.